Resveratrol Tames Dangerous Immune Traps Linked to Aging and Disease
A new review reveals how resveratrol suppresses neutrophil extracellular traps — immune structures tied to COVID-19, cancer, and organ injury.
Summary
Neutrophil extracellular traps (NETs) are web-like immune structures released by white blood cells that, when overactivated, drive inflammation and tissue damage in diseases like COVID-19, cancer, and lung injury. This 2025 review examines how resveratrol — a natural polyphenol found in grapes and berries — may inhibit excessive NET formation and the process called NETosis. Researchers analyzed multiple disease models and found resveratrol acts through anti-inflammatory, antioxidant, and immunomodulatory pathways to reduce harmful NET activity. While findings are promising, the authors caution that optimal dosing and precise mechanisms still require further clinical investigation.
Detailed Summary
Neutrophil extracellular traps (NETs) were once considered a clever immune defense — sticky webs of DNA and proteins that neutrophils deploy to catch pathogens. However, research has increasingly shown that excessive or dysregulated NETosis contributes to a wide range of serious conditions, including acute lung injury, COVID-19 complications, cancer progression, and hepatic ischemia-reperfusion injury. Understanding how to modulate NETs therapeutically has become a priority in immunology and longevity medicine.
This comprehensive 2025 review, published in Mutation Research Reviews, focuses on resveratrol — a polyphenolic compound naturally occurring in grapes, red wine, and certain berries — as a potential modulator of NET formation and release. The authors systematically examined the molecular mechanisms underlying NETosis and how resveratrol interacts with these pathways across multiple disease contexts.
Key findings suggest resveratrol can inhibit NET formation and reduce NET stability through its well-documented anti-inflammatory and antioxidant properties. In models of COVID-19 and acute lung injury, resveratrol appeared to dampen the cytokine storms and oxidative stress that trigger excessive NETosis. In cancer models, reduced NET activity may limit tumor-promoting inflammation and metastatic spread. Hepatic ischemia-reperfusion injury models similarly showed attenuation of NET-driven tissue damage.
The proposed mechanisms include resveratrol's ability to suppress reactive oxygen species (ROS), modulate NF-κB signaling, and influence neutrophil activation pathways — all of which feed into NETosis. Its immunomodulatory effects may recalibrate neutrophil behavior without fully suppressing immune defense.
However, the authors are candid about limitations. Most evidence comes from preclinical models, and translating these findings to human clinical practice requires rigorous trials. Optimal dosing, bioavailability challenges, and the complexity of NET biology in diverse diseases remain unresolved. This review nonetheless positions resveratrol as a compelling candidate for further investigation in NET-associated inflammatory and age-related disorders.
Key Findings
- Resveratrol inhibits excessive NET formation across multiple disease models including COVID-19 and lung injury.
- Anti-inflammatory and antioxidant mechanisms — including ROS suppression and NF-κB modulation — underlie resveratrol's effects on NETosis.
- In cancer models, resveratrol-mediated NET reduction may limit tumor-promoting inflammation and metastatic potential.
- Resveratrol attenuated NET-driven tissue damage in hepatic ischemia-reperfusion injury models.
- Optimal dosing and precise molecular mechanisms in humans remain unclear and require further clinical research.
Methodology
This is a narrative review synthesizing preclinical and mechanistic studies on resveratrol's effects on NETs and NETosis across disease models. The authors reviewed evidence from in vitro, animal, and disease-specific models including lung injury, COVID-19, cancer, and hepatic ischemia-reperfusion injury. No original experimental data were generated; conclusions are based on existing published literature.
Study Limitations
The review is based primarily on preclinical models, limiting direct applicability to human clinical practice. Resveratrol's well-known bioavailability challenges — rapid metabolism and low systemic absorption — are not fully resolved and may affect real-world efficacy. The authors acknowledge that detailed mechanistic pathways and optimal therapeutic dosages in humans remain to be established through dedicated clinical trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.